Kiromic BioPharma files two IND applications for CAR-T therapy in cancer

 

• Nano-cap Kiromic BioPharma (KRBP +6.8%) has announced the submission of two investigational new drug (IND) applications with the FDA for the initiation of two separate Phase 1 trials of an allogenic CAR-T administered intravenously and intrapleural/intraperitoneal for the treatment of epithelial ovarian carcinoma and malignant pleural mesothelioma.
• Kiromic’s proprietary PD1 Gamma-delta CAR (PD1-GDT CAR) T cell therapy is “off-the-shelf” allogeneic CAR T cells derived from healthy donors.
• The initial dose escalation component of each CAR-T trial is projected to enroll approximately 12 patients over 4 months at two sites. First in-human dosing is targeted for 1Q-2021.
• https://seekingalpha.com/news/3645464-kiromic-biopharma-files-two-ind-applications-for-car-t-therapy-in-cancer